Real-World data reveals how two drug combos stack up against melanoma

NCT ID NCT07091695

Completed Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two immunotherapy drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient characteristics, treatment patterns, and outcomes like survival and tumor response in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab + relatlimab or nivolumab + ipilimumab (immunotherapy drugs)
What this could lead to: If successful, this could help doctors understand which drug combination works better for melanoma patients before surgery, potentially improving treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors other than the drugs. It also only looks back at past data, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICALLY PALPABLE STAGE III RESECTABLE MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Cardinal Health

Dublin, Ohio, 43017, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.